(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of 20.49% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.27%.
Grail's revenue in 2026 is $165,263,000.On average, 11 Wall Street analysts forecast GRAL's revenue for 2026 to be $8,161,414,276, with the lowest GRAL revenue forecast at $7,528,940,403, and the highest GRAL revenue forecast at $8,770,215,046. On average, 11 Wall Street analysts forecast GRAL's revenue for 2027 to be $10,190,601,287, with the lowest GRAL revenue forecast at $8,964,513,164, and the highest GRAL revenue forecast at $11,734,266,334.
In 2028, GRAL is forecast to generate $13,050,580,250 in revenue, with the lowest revenue forecast at $10,374,179,509 and the highest revenue forecast at $16,424,220,904.